BRPI9913360B8 - proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada. - Google Patents

proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.

Info

Publication number
BRPI9913360B8
BRPI9913360B8 BRPI9913360A BR9913360A BRPI9913360B8 BR PI9913360 B8 BRPI9913360 B8 BR PI9913360B8 BR PI9913360 A BRPI9913360 A BR PI9913360A BR 9913360 A BR9913360 A BR 9913360A BR PI9913360 B8 BRPI9913360 B8 BR PI9913360B8
Authority
BR
Brazil
Prior art keywords
nucleic acid
vector
isolated
host cell
acid molecule
Prior art date
Application number
BRPI9913360A
Other languages
English (en)
Other versions
BR9913360A (pt
BR9913360B1 (pt
Inventor
Hershfield Michael
J Kelly Susan
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR9913360A publication Critical patent/BR9913360A/pt
Publication of BR9913360B1 publication Critical patent/BR9913360B1/pt
Publication of BRPI9913360B8 publication Critical patent/BRPI9913360B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção:<b>"oxidase de urato"<d>. a presente invenção refere-se, em geral, a proteínas de oxidase de urato (uricase) e moléculas de ácido nucléico codificando as mesmas. em particular, a invenção refere-se a proteínas de uricase as quais são particularmente úteis como, por exemplo, intermediários para produzir proteínas de uricase modificadas aperfeiçoadas com imunogenicidade reduzida e biodisponibilidade aumentada.
BRPI9913360A 1998-08-06 1999-08-05 proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada. BRPI9913360B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9548998P 1998-08-06 1998-08-06
PCT/US1999/017678 WO2000008196A2 (en) 1998-08-06 1999-08-05 Urate oxidase

Publications (3)

Publication Number Publication Date
BR9913360A BR9913360A (pt) 2001-07-03
BR9913360B1 BR9913360B1 (pt) 2013-09-24
BRPI9913360B8 true BRPI9913360B8 (pt) 2021-05-25

Family

ID=22252247

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913360A BRPI9913360B8 (pt) 1998-08-06 1999-08-05 proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.

Country Status (22)

Country Link
US (1) US7056713B1 (pt)
EP (2) EP1100880B1 (pt)
JP (3) JP2002524053A (pt)
KR (1) KR100841634B1 (pt)
CN (2) CN101280293B (pt)
AT (1) ATE483797T1 (pt)
AU (1) AU766421B2 (pt)
BR (1) BRPI9913360B8 (pt)
CA (1) CA2337967C (pt)
CY (1) CY1111001T1 (pt)
CZ (1) CZ304223B6 (pt)
DE (1) DE69942834D1 (pt)
DK (1) DK1100880T3 (pt)
ES (1) ES2352451T3 (pt)
HU (1) HU229774B1 (pt)
IL (3) IL141221A0 (pt)
NZ (1) NZ509633A (pt)
PL (1) PL207369B1 (pt)
PT (1) PT1100880E (pt)
RU (1) RU2290439C2 (pt)
WO (1) WO2000008196A2 (pt)
ZA (1) ZA200100974B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
JP2002524053A (ja) * 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PL202799B1 (pl) * 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
CN100371439C (zh) * 2003-04-07 2008-02-27 北京双鹭药业股份有限公司 一种重组假丝酵母尿酸氧化酶的制备方法
CN100334207C (zh) * 2004-04-27 2007-08-29 杭州北斗生物技术有限公司 一种黄曲霉尿酸氧化酶的制备方法
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
AU2011257764B2 (en) * 2005-04-11 2012-04-05 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
CN101622270B (zh) * 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
CN101402688B (zh) * 2008-11-18 2011-04-20 中国人民解放军军事医学科学院生物工程研究所 一种融合蛋白及其编码基因与应用
EP2411512B1 (en) 2009-03-24 2013-11-20 Meito Sangyo Co., Ltd. Improved type milk-clotting protease derived from a microorganism
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN102051348B (zh) 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
RU2460793C2 (ru) 2010-01-15 2012-09-10 Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) Способ получения l-аминокислот с использованием бактерий семейства enterobacteriaceae
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN103834623B (zh) * 2014-02-11 2017-11-07 中国药科大学 具有催化活性的人源尿酸氧化酶
CN104388467A (zh) * 2014-10-27 2015-03-04 李长贵 一种构建自发性高尿酸血症小鼠模型的方法及其用途
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN108103079B (zh) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
CN109554376B (zh) * 2018-11-13 2022-03-22 广西大学 一种碱性尿酸氧化酶及其在检测试剂盒和降低食品中尿酸的应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
CN111088268B (zh) * 2019-03-05 2022-08-02 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
CN118497161A (zh) 2019-05-10 2024-08-16 重庆派金生物科技有限公司 聚乙二醇修饰的尿酸氧化酶
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
MX2023001740A (es) * 2020-08-10 2023-04-05 Horizon Therapeutics Usa Inc Metodos de tratamiento de la gota.
CN111920942A (zh) * 2020-08-24 2020-11-13 深圳前海鹰岗生物科技有限公司 一种用于快速溶解痛风石的聚合物微针及制备方法和应用
EP4240423A1 (en) * 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN114438047B (zh) 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN112852772A (zh) * 2021-01-19 2021-05-28 中国科学院过程工程研究所 一种基于分子内交联和聚乙二醇修饰的尿酸氧化酶及其制备方法
CN112662640A (zh) * 2021-01-28 2021-04-16 中国药科大学 一种具有催化活性的尿酸氧化酶
CN113244412B (zh) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法
AU2022340814A1 (en) * 2021-09-01 2024-02-15 Ginkgo Bioworks, Inc. Recombinant cells for treating diseases associated with uric acid and methods of use thereof
WO2024138370A1 (zh) * 2022-12-27 2024-07-04 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
CN118360300A (zh) * 2023-01-10 2024-07-19 优环(苏州)生物医药科技有限公司 一种表达尿酸氧化酶的环状rna、制备方法及应用
CN119215150A (zh) 2023-06-28 2024-12-31 杭州远大生物制药有限公司 尿酸氧化酶及其聚乙二醇化缀合物的稳定剂及其药物用途
WO2025030053A1 (en) 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
CN119876069B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体
CN120005844B (zh) * 2025-04-22 2025-09-23 天津科技大学 人源尿酸氧化酶突变体及其制备方法与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pt)
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
FI972443L (fi) 1994-12-07 1997-06-09 Novo Nordisk As Polypeptidi, jonka allergeenisuus on vähentynyt
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
JP2002524053A (ja) * 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.

Also Published As

Publication number Publication date
HK1037214A1 (en) 2002-02-01
IL141221A (en) 2010-06-16
JP2010158244A (ja) 2010-07-22
KR100841634B1 (ko) 2008-06-26
IL197339A0 (en) 2011-07-31
WO2000008196A3 (en) 2000-03-30
EP1100880B1 (en) 2010-10-06
CY1111001T1 (el) 2015-06-11
CN1322243A (zh) 2001-11-14
WO2000008196A2 (en) 2000-02-17
WO2000008196A9 (en) 2000-07-13
KR20010053633A (ko) 2001-06-25
HU229774B1 (en) 2014-07-28
HUP0103205A3 (en) 2006-01-30
CA2337967A1 (en) 2000-02-17
JP2013215199A (ja) 2013-10-24
RU2290439C2 (ru) 2006-12-27
HK1153508A1 (en) 2012-03-30
EP2277998B1 (en) 2016-04-20
ES2352451T3 (es) 2011-02-18
CN101280293B (zh) 2013-09-11
DE69942834D1 (de) 2010-11-18
EP2277998A1 (en) 2011-01-26
CZ2001466A3 (cs) 2001-07-11
IL197339A (en) 2015-02-26
JP5721954B2 (ja) 2015-05-20
US7056713B1 (en) 2006-06-06
NZ509633A (en) 2003-04-29
JP2002524053A (ja) 2002-08-06
PT1100880E (pt) 2011-01-13
HUP0103205A2 (hu) 2001-12-28
AU5336599A (en) 2000-02-28
BR9913360A (pt) 2001-07-03
HK1125402A1 (en) 2009-08-07
IL141221A0 (en) 2002-03-10
CA2337967C (en) 2011-11-01
DK1100880T3 (da) 2011-01-24
PL207369B1 (pl) 2010-12-31
ATE483797T1 (de) 2010-10-15
EP1100880A4 (en) 2002-04-17
PL346222A1 (en) 2002-01-28
BR9913360B1 (pt) 2013-09-24
ZA200100974B (en) 2002-06-26
CN101280293A (zh) 2008-10-08
EP1100880A2 (en) 2001-05-23
AU766421B2 (en) 2003-10-16
CZ304223B6 (cs) 2014-01-15

Similar Documents

Publication Publication Date Title
BRPI9913360B8 (pt) proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.
BR9804896A (pt) Dna isolado e purificado, célula hospedeira, vetor, polinucleotídeo quimérico, plasmídeo e processo para aumentar a transcrição de um gene de interesse em uma célula hospedeira
ATE471370T1 (de) Varianten von beta-glukosidasen
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
WO2005003296A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
BRPI0516176A (pt) polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
BR0213774A (pt) Molécula de ácido nucleio isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
WO2000004162A3 (en) Genes encoding sulfate assimilation proteins
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU3422200A (en) Heat-inducible promoter
WO2002062964A3 (en) Ap1 amine oxidase variants
ATE288491T1 (de) Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren
WO2001016325A3 (en) Plant reproduction proteins
AU7645400A (en) Polypeptides having glucanotransferase activity and nucleic acids encoding same
WO2003054181A3 (en) Nucleic acid labeling by thermoanaerobacter thermohydrosulfuricus dna polymerase i variants
DE69925927D1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
EP0897984A3 (en) D-Sorbitol dehydrogenase gene
Zalipsky et al. Reversible PEGylation: Thiolytic regeneration of active protein from its polymer conjugates
WO2005003289A3 (en) Ap1 amine oxidase variants
WO2000064464A8 (en) NUCLEIC ACIDS AND PROTEINS OF A RAT GANGLIOSIDE GM1-SPECIFIC αl→2FUCOSYLTRANSFERASE AND USES THEREOF
WO1999036530A3 (en) Lh-receptor gene promoter for tissue-specific gene expression
WO1999053082A3 (en) Hexose carrier proteins

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A REQUERENTE DEVERA SANAR TAL IRREGULARIDADE COMPLETANDO A TAXA RELATIVA A 02 REIVINDICACOES EXCEDENTES.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE DEFERIMENTO NOTIFICADO NA RPI NO 2188 DE 11/12/2012. UMA VEZ QUE SE CONSTATOU QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECAO NO NUMERO DA PETICAO DE DEPOSITO (CITADO NO 0016184200 QUANDO O CORRETO E NO 00161842100), RETIFICA-SE A REFERIDA PUBLICACAO:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B24E Patent annual fee: resolution cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.10 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2473 DE 29/05/2018 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 05/08/2019